Characteristics of patients with and without GVHD, defined as acute grade II-IV or chronic GVHD
| . | Developed GVHD . | Did not develop GVHD . |
|---|---|---|
| No. of patients | 24 | 13 |
| Median age (range) | 57 (35-66) | 58 (22-64) |
| Male sex (%) | 15 (62) | 5 (38) |
| AML/MDS | 9/15 | 8/5 |
| Early disease phase* (%) | 7 (29) | 8 (61) |
| Sex mismatch (%) | 9 (37) | 6 (46) |
| 100% donor chimerism in PB on d +30 (%) | 15 (62) | 9 (69) |
| Achieved > 95% donor chimerism (%) before d +100* | 18/20 (90) | 7/11 (64) |
| TRM (%) | 2 (8) | 1 (8) |
| Follow-up, in d*(range) | 330 (69-1156) | 124 (61-489) |
| . | Developed GVHD . | Did not develop GVHD . |
|---|---|---|
| No. of patients | 24 | 13 |
| Median age (range) | 57 (35-66) | 58 (22-64) |
| Male sex (%) | 15 (62) | 5 (38) |
| AML/MDS | 9/15 | 8/5 |
| Early disease phase* (%) | 7 (29) | 8 (61) |
| Sex mismatch (%) | 9 (37) | 6 (46) |
| 100% donor chimerism in PB on d +30 (%) | 15 (62) | 9 (69) |
| Achieved > 95% donor chimerism (%) before d +100* | 18/20 (90) | 7/11 (64) |
| TRM (%) | 2 (8) | 1 (8) |
| Follow-up, in d*(range) | 330 (69-1156) | 124 (61-489) |
All P values are > .2 except for early disease phase (P = .08), having achieved greater than 95% donor chimerism before day + 100 (P = .07) and follow-up (P = .04).